With COPD, the limitation of airflow is not fully reversible, which leads to a gradual loss of lung function. Early detection may change the course and progression of the disease. There are variety of inhalers in the market for the treatment of COPD. First-line therapies are dependent upon...
Early detection and appropriate management of chronic obstructive pulmonary disease (COPD) may help to reduce the high mortality and morbidity associated with this disease. New pharmacological treatments for COPD, along with the implementation of recommendations of the National Strategy for COPD due for ...
COPD is one of the most common diseases in the world, and there is a global increase in prevalence, but there are no drugs available at present that halt the relentless progression of this disease. However, a better understanding of the cellular and molecular mechanisms that are involved in ...
New treatment strategies for COPD. Postgrad Med 2005;117(3):27.Cote CG, Celli BR. New treatment strategies for COPD. Pairing the new with the tried and true. Postgrad Med 2005;117(3):27- 34.Cote CG, Celli BR. New treatment strategies for COPD: pairing the new with the tried and ...
Modern Bronchoscopic Treatment Options for Patients with Chronic Bronchitis Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of death worldwide and has a large impact on a patient's quality of life due to i... AK Mayr,A Valipour - 《Journal of Clinical Medicine》 被...
“Millions of symptomatic COPD patients in the US are in urgent need of new treatment options,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma. “The NDA submission for ensifentrine is a significant milestone towar...
“Millions of symptomatic COPD patients in the US are in urgent need of new treatment options,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma. “The NDA submission for ensifentrine is a signif...
“Millions of symptomatic COPD patients in the US are in urgent need of new treatment options,” says David Zaccardelli, president and CEO of Verona Pharma, in a release. “The NDA submission for ensifentrine is a significant milestone towards our goal of bringing th...
(COPD) is to bring you up to speed quickly on all the information you need to know about COPD.1 The 2008 update includes guidance on using new treatment options that have emerged since the last guidelines were published in 2003,2 new data about the epidemiology of COPD, and information ...
Inebilizumab-cdon is only the second approved treatment for neuromyelitis optica spectrum disorder, according to the FDA. The FDA has approved inebilizumab-cdon (Uplizna, Viela Bio) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patient...